|
| |
Start Date: 3/1/2010 End Date:3/15/2010
| How will the results of the CREST study impact the use of carotid stenting? |
| Increase the use of carotid stenting |
|
|
| Increase the use of carotid endarterectomy |
|
|
|
Start Date: 2/15/2010 End Date:3/15/2010
| Among the following societies, which one represent best the interventional cardiology community? |
|
|
|
|
Start Date: 2/1/2010 End Date:2/26/2010
| What is the main reason for not using Prasugrel for patients with ACS? |
|
| Don't have it in the Cath lab |
|
|
|
| Patients pre loaded with Clopidogrel |
|
|
Start Date: 1/25/2010 End Date:2/25/2010
| When you need to perform PCI to a second vessel what is your practice in relates to timing? |
| The same procedure if there are no renal impairment |
|
|
|
| In 4-6 weeks from the PCI to the primary vessel |
|
|
Start Date: 1/11/2010 End Date:2/14/2010
| What should be the primary endpoint for CABG versus PCI study for unprotected LM? |
|
|
|
Start Date: 12/21/2009 End Date:1/21/2010
| Which of the studies published or presented in 2009 will make most impact in 2010? |
|
|
|
|
|
|
|
Start Date: 12/7/2009 End Date:12/30/2009
| Which PFO should be closed? |
|
|
| Only post stroke and for migraine |
|
|
Start Date: 11/23/2009 End Date:12/23/2009
| How did the FDA warning in regards to an interaction between clopidogrel and the PPI will impact your practice? |
|
| Less use of PPI with clopidogrel |
|
|
| Less use of clopidogrel with PPI |
|
|
|
Start Date: 11/16/2009 End Date:11/24/2009
| Do you support performing elective PCI in hospitals without surgical backup? |
|
|
Start Date: 11/2/2009 End Date:11/20/2009
| Do you believe that there is sufficient evidence to change the guidelines in regards to PCI of unprotected LM? |
|
|
Start Date: 10/19/2009 End Date:11/20/2009
| How will the latest data from Current Oasis 7 change antiplatelet practice for patients with ACS? |
|
| More use of 600 mg versus (300 mg) as a loading dose |
|
|
| More use of 600 mg and 150 mg for the first week after PCI |
|
|
|
Start Date: 10/5/2009 End Date:10/29/2009
| How will the recent data on FFR (FAME)and IVUS (PROSPECT) will change their use in the cath lab? |
|
|
|
|
Start Date: 9/23/2009 End Date:10/29/2009
| Do you support the public option for healthcare reform? |
|
|
Start Date: 9/14/2009 End Date:9/29/2009
| What is your prediction to the results of SPIRIT IV: Xience V versus TAXUS Express? |
| XIENCE V superior for MACE |
|
|
| XIENCE V superior to TAXUS for TVF but non-inferior for TLR |
|
|
| XIENCE V non-inferior to TAXUS for MACE |
|
|
Start Date: 8/31/2009 End Date:9/14/2009
| What is the usage of FFR in your lab? |
|
|
|
|
Start Date: 8/24/2009 End Date:9/8/2009
| What is your prediction to the results of OASIS 7 study (higher loading dose (600 mg) and maintenance dose (150 mg daily) of Clopidogrel)? |
| Improved efficacy; no difference in bleeding |
|
|
| Improved efficacy but more bleeding |
|
|
| No difference in efficacy; no difference in bleeding |
|
|
| No difference in efficacy; but more bleeding |
|
|
Start Date: 8/10/2009 End Date:8/26/2009
| For patients with cardiogenic shock which device is more effective for hemodynamic support? |
|
|
|
| No major differences among the available devices |
|
|
Start Date: 7/27/2009 End Date:8/12/2009
| Will the use of DES increase with the approval of Prasugrel (Effient)? |
|
|
Start Date: 7/13/2009 End Date:7/29/2009
| How often will you use Prasugrel (Effient) for patients with acute MI? |
|
|
|
|
Start Date: 7/6/2009 End Date:7/13/2009
| Should the guidelines for PCI for unprotected LM be changed from class III? |
|
|
| No, more studies are needed |
|
|
Start Date: 6/22/2009 End Date:7/23/2009
| Do you support the new health care plan? |
|
|
Start Date: 6/15/2009 End Date:6/24/2009
| What will be the impact of the BARI 2D study results on the revascularization volume in diabetic patients? |
|
|
|
|
Start Date: 6/8/2009 End Date:6/20/2009
| Do you believe that proton pump inhibitors impacts platelet responsiveness? |
|
| Yes, but should not change the practice |
|
|
| Yes, but should not be prescribed to patients with DES on Plavix |
|
|
Start Date: 5/26/2009 End Date:6/26/2009
| Will the SYNTAX score be adopted by the interventional cardiology community? |
|
|
| I don't know what the SYNTAX score is. |
|
|
Start Date: 5/18/2009 End Date:5/27/2009
| Do you believe that DES with bioabsorbable polymers are safer when compared to DES with durable polymers? |
|
|
Start Date: 5/11/2009 End Date:5/20/2009
| What is the main reason not to use the radial approach? |
| Lack of knowledge/ training |
|
|
|
| I feel more comfortable with femoral access |
|
|
Start Date: 5/4/2009 End Date:5/13/2009
| What is the most important feature that influences DES selection? |
|
|
|
Start Date: 4/27/2009 End Date:5/5/2009
| The FDA advisory panel voted 7 to 5 to recommend the approval of the Watchman LAA closure device. Do you agree? |
|
|
Start Date: 4/20/2009 End Date:4/29/2009
| Which pattern of days do you prefer for interventional cardiology meetings? |
| Sunday, Monday and Tuesday |
|
|
| Monday, Tuesday and Wednesday |
|
|
| Wednesday, Thursday and Friday |
|
|
Start Date: 4/13/2009 End Date:4/22/2009
| Should patients be loaded with high dose Statin prior to PCI (ARMYDA-RECAPTURE)? |
|
| Only in elective patients |
|
|
| Need larger data to support this strategy |
|
|
Start Date: 4/6/2009 End Date:4/14/2009
| How frequently should radial access for PCI be used? |
|
|
|
Start Date: 3/30/2009 End Date:4/8/2009
| Do you believe that the FDA will approve marketing the Watchman device for atrial appendage closure based on the PROTECT AF data? |
|
|
Start Date: 3/23/2009 End Date:3/31/2009
| Should all non-responsive patients post CPR undergo cooling protocol? |
|
|
| Not familiar with the data |
|
|
Start Date: 3/16/2009 End Date:3/25/2009
| Should live cases in interventional courses be regulated by FDA and CME? |
|
|
Start Date: 3/9/2009 End Date:3/17/2009
| For patients undergoing PCI with DES, should the Clopidogrel dose be routinely tailored based on responsiveness? |
|
|
| Only in high risk patients |
|
|
Start Date: 3/2/2009 End Date:3/11/2009
| Will you use the Syntax score to determine who should undergo PCI or CABG? |
|
|
| I am not familiar with the Syntax score |
|
|
Start Date: 2/23/2009 End Date:3/3/2009
| Do you believe that the second generation drug-eluting stents are associated with less stent thrombosis when compared with the first generation Cypher and Taxus? |
|
|
Start Date: 2/16/2009 End Date:2/24/2009
| Would you continue to come to the major cardiology and interventional cardiology meetings if CME was not provided? |
|
|
Start Date: 2/9/2009 End Date:2/19/2009
| Will Prasugrel replace Clopidogrel once approved by the FDA? |
| Yes, in the majority of the patients |
|
|
| No, it will only be used for high risk patients with stent thrombosis |
|
|
| Yes, in the hospital, but patients will be prescribed Plavix upon discharge |
|
|
Start Date: 2/2/2009 End Date:2/9/2009
| Do you agree with the proposed legislation that drug and medical device manufacturers would need to publicly disclose all physician payments and gifts exceeding $100? |
|
|
Start Date: 1/26/2009 End Date:2/2/2009
| How will the results of the FAME study impact your practice in the cath lab? |
| I will increase the use of FFR |
|
|
| I will avoid angioplasty in intermediate lesions |
|
|
| The results will not impact my practice |
|
|
Start Date: 1/19/2009 End Date:1/26/2009
| What are your thoughts regarding the PCI guidelines? |
| I am familiar and adhere to the guidelines |
|
|
| I am familiar but do not adhere to the guidelines |
|
|
| There are too many guidelines |
|
|
| I am not familiar with the guidelines |
|
|
Start Date: 1/12/2009 End Date:1/19/2009
| What is the main reason for premature Plavix cessation? |
|
|
|
| Patients on too many pills |
|
|
Start Date: 1/5/2009 End Date:1/12/2009
| Is there a shortage of interventional cardiologists in your area? |
|
|
Start Date: 12/22/2008 End Date:1/6/2009
| Which of the following studies presented in 2008 will make most impact on clinical practice in 2009? |
|
|
|
|
|
Start Date: 12/15/2008 End Date:12/22/2008
| Will OCT have a role in clinical practice? |
|
|
|
Start Date: 12/8/2008 End Date:12/15/2008
| When do you use vascular closure devices? |
| All diagnostic and PCI cases |
|
|
|
| In PCI but not frequently |
|
|
Start Date: 12/1/2008 End Date:12/8/2008
| Do live case demonstrations jeopardize patient safety? |
|
|
Start Date: 11/24/2008 End Date:12/1/2008
| How does the economic crisis impact the cath lab in your hospital? |
| More patients with normal coronaries |
|
|
|
| Pressure from the administration on cost saving |
|
|
|
Start Date: 11/17/2008 End Date:11/24/2008
| How will the JUPITER study results impact your practice? |
| Order more hsCRP levels on low risk patients |
|
|
|
| Increase the use of statins not limited to Crestor |
|
|
| The study results will not impact my practice |
|
|
Start Date: 11/10/2008 End Date:11/17/2008
| Is there an application for the drug coated balloon? |
| Coronary use (ISR, bifurcation, de-novo) |
|
|
| Peripheral use (SFA, CLI) |
|
|
| Both coronary and peripheral |
|
|
|
Start Date: 11/3/2008 End Date:11/10/2008
| Should the Clopidogrel dose be adjusted based on testing for responsiveness? |
|
|
| Only for high risk patients for stent thrombosis |
|
|
Start Date: 10/27/2008 End Date:11/3/2008
| How often should IIB/IIIA inhibitors be used for primary PCI of patients with AMI? |
|
|
|
| Only when a clot is visible |
|
|
Start Date: 10/20/2008 End Date:10/27/2008
| How will the results of the Horizons AMI study impact the use of DES for AMI? |
| The results will increase the use of DES for AMI |
|
|
| The results will decrease the use of DES for AMI |
|
|
| The results will not change anything |
|
|
Start Date: 10/13/2008 End Date:10/20/2008
| Whose health care plan do you favor? |
|
|
|
Start Date: 10/6/2008 End Date:10/13/2008
| What is your prediction as to the results of the HORIZION-AMI (Taxus (DES) vs. Express (BMS) in patients with STEMI) trial? |
| Taxus is superior to Express |
|
|
| Taxus is non-inferior to Express |
|
|
| TAXUS reduced TLR but was less safe than Express |
|
|
Start Date: 9/29/2008 End Date:10/6/2008
| In your practice, for what percentage of patients it is realistic to achieve door to balloon time < 90 minutes? |
|
|
|
Start Date: 9/22/2008 End Date:9/29/2008
| Should the Advisory panel to the FDA recommend approval of Prasugrel for marketing? |
|
|
Start Date: 9/15/2008 End Date:9/22/2008
| How will the results of the SYNTAX study impact your practice on patients with multivessel disease and unprotected LM? |
|
|
|
Start Date: 9/8/2008 End Date:9/14/2008
| Do you believe that biodegradable polymers have an advantage in a DES? |
|
|
Start Date: 9/1/2008 End Date:9/7/2008
| Which of the following DES is the most effective for diabetic patients? |
|
|
|
|
| No difference among these stents |
|
|
Start Date: 8/25/2008 End Date:8/31/2008
| Will the SYNTAX study meets its primary clinical endpoint? |
|
|
|
Start Date: 8/18/2008 End Date:8/25/2008
| What impact will the quality of life data from the COURAGE trial have on PCI volume? |
| The data will increase PCI volume |
|
|
| The data will decrease PCI volume |
|
|
| The data will not influence PCI volume |
|
|
Start Date: 8/11/2008 End Date:8/20/2008
| What is the primary stent that XIENCE V / PROMOUS replaced in your lab? |
|
|
|
|
Start Date: 8/4/2008 End Date:8/10/2008
| What could be the main role of drug eluting balloons in PCI? |
|
| Treatment of in-stent restenosis |
|
|
| Denovo lesions with and without BMS |
|
|
|
Start Date: 7/28/2008 End Date:8/3/2008
| What is the best approach for patients with diffuse DES in-stent restenosis? |
|
|
|
|
Start Date: 7/21/2008 End Date:7/27/2008
| How is your PCI volume compared to last year? |
|
|
|
Start Date: 7/14/2008 End Date:7/20/2008
| What is your preferred lipid lowering agent in 2008? |
|
|
|
|
Start Date: 7/7/2008 End Date:7/13/2008
| With the approval of Xience, which of the four available stents will be your workhorse stent? |
|
|
|
|
Start Date: 6/30/2008 End Date:7/6/2008
| With the approval of Endeavor and Xience V/Promus what will determine your DES selection? |
|
|
|
|
Start Date: 6/23/2008 End Date:6/29/2008
| Which is your preferred hemodynamic support device for high risk PCI? |
|
|
|
Start Date: 6/16/2008 End Date:6/22/2008
| Which of the following societies best represents the field of interventional cardiology? |
|
|
|
|
Start Date: 6/9/2008 End Date:6/15/2008
| How many cardiology journals do you read per month? |
|
|
|
|
Start Date: 6/2/2008 End Date:6/8/2008
| What is the best method of assessing an intermediate lesion? |
| Fractional Flow Reserve (FFR) |
|
|
| Intravascular Ultrasound (IVUS) |
|
|
|
Start Date: 5/26/2008 End Date:6/1/2008
| What is your preferred anticoagulant in patients with STEMI undergoing primary PCI? |
|
| Bivalirudin and GpIIB/IIIA inhibitors |
|
|
|
| Heparin and GpIIB/IIIA inhibitors |
|
|
Start Date: 5/19/2008 End Date:5/25/2008
| Which of the DES would you choose to use for your own family member? |
|
|
|
|
Start Date: 5/12/2008 End Date:5/18/2008
| Do you see an increase in PCI for unprotected LM disease? |
|
|
Start Date: 5/5/2008 End Date:5/11/2008
| Do you beleive that PCI can be performed safely in hospitals without onsite CABG? |
|
|
Start Date: 4/28/2008 End Date:5/4/2008
| Who would you like to see win the Democratic nomination for President? |
|
|
Start Date: 4/21/2008 End Date:4/27/2008
| Which stent should patients with AMI get? |
|
|
Start Date: 4/14/2008 End Date:4/20/2008
| Do you think that there is enough data to support FDA approval for Prasugrel? |
|
|
Start Date: 4/7/2008 End Date:4/13/2008
| In what configuration would you like to see the future i2 ACC /SCAI meetings? |
|
| Joint meeting apart from the ACC |
|
|
| Two separate meetings at different venues |
|
|
Start Date: 3/31/2008 End Date:4/6/2008
| Do you believe that the ENDEAVOR STENT is safer than TAXUS or CYPHER |
|
|
Start Date: 3/24/2008 End Date:3/30/2008
| In which DES do you see more stent fractures? |
| Never see stent fractures |
|
|
|
|
Start Date: 3/17/2008 End Date:3/23/2008
| Which DES you prefer for diabetic patients? |
|
|
|
|
Start Date: 3/10/2008 End Date:3/16/2008
| Should high risk patients for DES thrombosis undergo routine evaluation for aspirin and plavix resistance? |
|
|
Start Date: 3/3/2008 End Date:3/9/2008
| Which reservoir do you prefer for a DES system? |
|
|
Start Date: 2/25/2008 End Date:3/2/2008
| How often do you use distal protection devices for PCI of SVG? |
|
|
|
Start Date: 2/12/2008 End Date:2/24/2008
| Do you believe that there is a rebound phenonmenon after cessation of clopidogrel? |
|
|
Start Date: 2/4/2008 End Date:2/11/2008
| Now that Endeavor has received FDA approval, how will you use Endeavor in the lab? |
| Replacing the other approved DES |
|
|
|
| Replacing both of the other DES and BMS |
|
|
Start Date: 1/28/2008 End Date:2/3/2008
| How will the latest NEJM publication comparing DES vs BMS for off-label use influence your practice? |
|
|
|
Start Date: 1/21/2008 End Date:1/27/2008
| How did the results of the ENHANCE study impact your prescription volume of Vytorin? |
|
|
| I am not aware of the ENHANCE study |
|
|
Start Date: 1/14/2008 End Date:1/20/2008
| In the 2008 presidential race, which candidates have the best health care platform? |
| The Democratic candidates |
|
|
| The Republican candidates |
|
|
Start Date: 1/7/2008 End Date:1/13/2008
| Do you believe that lowering the price of DES will increase their use substantially? |
|
|
Start Date: 12/24/2007 End Date:1/6/2008
| Which of the following studies presented in 2007 will have the most impact on your clinical practice in 2008? |
|
|
|
| SCHARR (Swedish DES registry) |
|
|
|
|
Start Date: 12/17/2007 End Date:12/23/2007
| What is your opinion on the AHA/ACC Guidelines for STEMI and NSTEMI? |
| The guidelines should only be a recommendation to guide therapy |
|
|
| They should be enforced with reimbursement only for those who adhere to them |
|
|
Start Date: 12/10/2007 End Date:12/16/2007
| Do you feel that imaging vulnerable plaque with virtual histology, OCT, or intravascular MRI will be clinically useful? |
|
|
Start Date: 12/3/2007 End Date:12/9/2007
| Do you agree that the one year data on the safety and efficacy of the new generation of DES is sufficient for approval for marketing? |
|
|
Start Date: 11/26/2007 End Date:12/2/2007
| Is there value in detecting a vulnerable plaque in coronary arteries using invasive imaging technology? |
|
|
Start Date: 11/19/2007 End Date:11/25/2007
| Do you believe that patients with positive exercise stress tests should be referred directly to cath or to 64 CT angiography? |
| Directly to cath; no need for CT |
|
|
| Directly to CT; cath if CT positive |
|
|
Start Date: 11/12/2007 End Date:11/18/2007
| What is the main reason for volume reduction in PCI? |
|
| The results of the COURAGE trial |
|
|
|
| More smoking cessation and optimal medical therapy |
|
|
Start Date: 11/5/2007 End Date:11/11/2007
| In TRITON TIMI 38 Prasugrel showed less cardiac mortality and stent thrombosis, but more death from bleeding. Would you like to see the drug approved for marketing by the FDA? |
|
|
Start Date: 10/29/2007 End Date:11/4/2007
| What is your opinion regarding PCI and its relation to gender? |
| Similar efficacy in women vs men |
|
|
| Similar efficacy but more bleeding in women |
|
|
| Better efficacy and safety in men |
|
|
Start Date: 10/15/2007 End Date:10/28/2007
| Do you feel comfortable using Bivalirudin as the primary thrombin inhibitor for patients with acute MI? |
|
|
Start Date: 10/8/2007 End Date:10/14/2007
| What do you think will happen to DES useage in 2008? |
|
|
|
Start Date: 10/1/2007 End Date:10/7/2007
| How will approval of Endeavor in the US impact the market share of DES and BMS? |
|
|
|
| Decrease use of Cypher and Taxus |
|
|
| Decrease use of all three |
|
|
Start Date: 9/24/2007 End Date:9/30/2007
| Do you see an increase in in-stent restenosis since you shifted from DES to BMS? |
|
|
Start Date: 9/17/2007 End Date:9/23/2007
| What is your impression following the latest published meta anlaysis of Cypher versus Taxus? |
| Cypher is superior to Taxus |
|
|
| Taxus is superior to Cypher |
|
|
| There are no significant differences between the two |
|
|
Start Date: 9/10/2007 End Date:9/16/2007
| Following the latest presentations on DES at the ESC 2007, what is your projection for the use of DES in 2008? |
|
|
|
Start Date: 8/27/2007 End Date:9/9/2007
| One year later, what do you think about presentations from ESC06 stating that DES is associated with higher mortality and MI compared to BMS? |
| The presentations were accurate |
|
|
| The presentations were misleading |
|
|
| The presentations were not accurate, but appropriately raised important issues |
|
|
Start Date: 8/20/2007 End Date:8/26/2007
| For low risk patients with UA/NSTEMI, what is your preferred treatment strategy? |
| Immediate (directly to the cath lab) |
|
|
| Conservative (with medical therapy first) |
|
|
Start Date: 8/13/2007 End Date:8/19/2007
| What is your preference for stent design in the treatment of bifurcation lesions? |
| A dedicated bifurcated stent design |
|
|
| A stent with an access to the branch |
|
|
| No need for a dedicated stent - most cases can be treat with conventional stents |
|
|
Start Date: 8/6/2007 End Date:8/12/2007
| What would you recommend to the FDA with regards to Rosiglitazone (Avandia) following the Circulatory Panel's recommendations? |
| To add a warning to the labeling of the drug |
|
|
| Wait for more trials before making any decision |
|
|
| Remove Rosiglitazone from the market |
|
|
Start Date: 7/30/2007 End Date:8/5/2007
| What needs to be done to increase PCI volume? |
| PCI volume will increase without any marketing |
|
|
| Target educational programs to internists and general practitioners |
|
|
| Target educational programs to patients directly |
|
|
| Explore new markets like peripheral intervention |
|
|
Start Date: 7/23/2007 End Date:7/29/2007
| What do you recommend for patients undergoing stenting for saphenous vein grafts > 3.5 mm? |
|
|
Start Date: 7/16/2007 End Date:7/22/2007
| Do you believe that routine use of aspiration catheters in primary PCI impacts clinical outcomes? |
|
|
Start Date: 7/9/2007 End Date:7/15/2007
| What is the main reason for the drop in DES use? |
|
| Requirement for prolonged dual antiplatelet therapy |
|
|
|
| Higher use of BMS in non-complex lesions |
|
|
Start Date: 7/2/2007 End Date:7/8/2007
| Do you believe that Rosiglitazone (Avandia) increases CV death and MI? |
|
|
Start Date: 6/25/2007 End Date:7/1/2007
| Do you feel that the American College of Cardiology (ACC) represents interventional cardiologists' needs? |
|
|
Start Date: 6/18/2007 End Date:6/24/2007
| For patients undergoing CABG, what is the preferred strategy? |
|
|
| Does not matter, will go with the surgeons choice |
|
|
Start Date: 6/11/2007 End Date:6/17/2007
| Do you believe that ENDEAVOR 4 (Endevaor versus Taxus) will meet its endpoints? |
|
|
Start Date: 6/4/2007 End Date:6/10/2007
| Do you routinely measure CRP in your PCI patients? |
|
|
Start Date: 5/28/2007 End Date:6/3/2007
| Which percutaneous aortic valve program is more appealing to you? |
|
|
Start Date: 5/21/2007 End Date:5/27/2007
| Based on the data presented so far, which among the following DES is the safest? |
|
|
|
|
|
Start Date: 5/14/2007 End Date:5/20/2007
| Do you think patients with ACS should be loaded with a high dose of statins prior to PCI? |
|
|
Start Date: 5/7/2007 End Date:5/13/2007
| What has the most impact on the reduction of PCI volume in your hospital? |
| Less restenosis with DES use |
|
|
| Opening PCI programs in small hospitals |
|
|
| Publication of the Courage trial |
|
|
| Less coronary artery disease in the community |
|
|
Start Date: 4/30/2007 End Date:5/6/2007
| Which Aspirin dose should be prescribed for patients undergoing PCI with DES? |
|
|
Start Date: 4/23/2007 End Date:4/29/2007
| Are you comfortable discharging patients undergoing uncomplicated PCI on the same day as their procedure? |
|
|
Start Date: 4/16/2007 End Date:4/22/2007
| Should patients with chest pain in the emergency room be evaluated with cardiac CT for coronary artery disease? |
|
|
Start Date: 4/9/2007 End Date:4/15/2007
| In the next 6 months, how do you anticipate DES use for PCI to change? |
|
|
|
Start Date: 4/2/2007 End Date:4/8/2007
| How will the results of the COURAGE trial will impact the PCI volume in the next year? |
|
| No change in PCI, but more medical therapy |
|
|
|
Start Date: 3/26/2007 End Date:4/1/2007
| What is your opinion in regards to the future use of bioabsorbable stents? |
| Major role in coronary and peripheral intervention |
|
|
|
| There is not enough data to have an opinion |
|
|
Start Date: 3/19/2007 End Date:3/25/2007
| What would you recommend for an asymptomatic non-diabetic patient with 75% stenosis in the proximal LAD? |
|
|
|
| | |